Efficacy outcomes

Lumbar spine BMD values at baseline, 6 months and 12 months in both the treatment arms. No significant difference in two groups at any time point.

% change in LS-BMD at 12 months. No significant difference (Both Intention to treat and per protocol analysis) noted between two groups.

Pharmacokinetic evaluation

Safety and Immunogenicity